Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31316528 | 0.83 | USP2 (0.40) | USP2SMN1; SMN2RECQLHDAC2 | |
| SCHEMBL31316650 | 0.82 | USP2 (0.40) | USP2SMN1; SMN2RECQL | |
| SCHEMBL31041013 | 0.79 | USP2 (0.59) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA | |
| SCHEMBL23439070 | 0.77 | USP2 (0.45) | USP2SMN1; SMN2RECQLHDAC2 | |
| SCHEMBL31299280 | 0.77 | USP2 (0.61) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA | |
| SCHEMBL30237873 | 0.77 | USP2 (0.45) | USP2SMN1; SMN2RECQLHDAC2 | |
| SCHEMBL16903431 | 0.77 | USP2 (0.61) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA | |
| SCHEMBL31299440 | 0.77 | USP2 (0.61) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA | |
| SCHEMBL25866966 | 0.76 | USP2 (0.63) | USP2SMN1; SMN2RECQLHDAC2 | |
| SCHEMBL23707226 | 0.75 | USP2 (0.58) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | USP2 3635/4885SMN1; SMN2 3059/4885RECQL 90/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | USP2 3246/4885SMN1; SMN2 1780/4885RECQL 721/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | USP2 3635/4885SMN1; SMN2 3059/4885RECQL 90/4885 |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | USP2 3635/4885SMN1; SMN2 3059/4885RECQL 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.